Reuters logo
BRIEF-Ose Immunotherapeutics To Resume Accrual In Phase 3 Trial Of Tedopi
December 7, 2017 / 6:39 AM / 10 days ago

BRIEF-Ose Immunotherapeutics To Resume Accrual In Phase 3 Trial Of Tedopi

Dec 7 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* TO RESUME ACCRUAL IN PHASE 3 TRIAL OF TEDOPI FOLLOWING IMMUNE CHECKPOINT INHIBITOR TREATMENT

* CLINICAL TRIAL ON PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below